The radioimmunotherapy market is expanding rapidly as demand surges for personalized and targeted cancer treatments. Valued at USD 3.13 billion in 2025, the market is projected to exceed USD 12.70 billion by 2034, growing at a CAGR of 16.83% driven by rising cancer prevalence, technological advancements, and increased R&D investment in next-generation therapies.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Radioimmunotherapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Radioimmunotherapy Market Revenue and Volume Forecast, by Indication
8.1.1. Hodgkin lymphoma
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Leukemia
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Non-Hodgkin lymphoma
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Multiple Myeloma
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Volume Forecast
9.1. Radioimmunotherapy Market Revenue and Volume Forecast, by Target Antigen
9.1.1. CD33
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. CD20
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. CD52
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. CD19
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Volume Forecast
10.1. Radioimmunotherapy Market Revenue and Volume Forecast, by Radioisotope
10.1.1. Yttrium-90
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Lutetium-177
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Thallium-201
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Iodine-131
10.1.4.1. Market Revenue and Volume Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Volume Forecast
11.1. Radioimmunotherapy Market Revenue and Volume Forecast, by Administration Route
11.1.1. Intrathecal
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Intravenous
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Intraperitoneal
11.1.3.1. Market Revenue and Volume Forecast
11.1.4. Others
11.1.4.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Indication
12.1.2. Market Revenue and Volume Forecast, by Target Antigen
12.1.3. Market Revenue and Volume Forecast, by Radioisotope
12.1.4. Market Revenue and Volume Forecast, by Administration Route
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Indication
12.1.5.2. Market Revenue and Volume Forecast, by Target Antigen
12.1.5.3. Market Revenue and Volume Forecast, by Radioisotope
12.1.5.4. Market Revenue and Volume Forecast, by Administration Route
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Indication
12.1.6.2. Market Revenue and Volume Forecast, by Target Antigen
12.1.6.3. Market Revenue and Volume Forecast, by Radioisotope
12.1.6.4. Market Revenue and Volume Forecast, by Administration Route
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Indication
12.2.2. Market Revenue and Volume Forecast, by Target Antigen
12.2.3. Market Revenue and Volume Forecast, by Radioisotope
12.2.4. Market Revenue and Volume Forecast, by Administration Route
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Indication
12.2.5.2. Market Revenue and Volume Forecast, by Target Antigen
12.2.5.3. Market Revenue and Volume Forecast, by Radioisotope
12.2.5.4. Market Revenue and Volume Forecast, by Administration Route
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Indication
12.2.6.2. Market Revenue and Volume Forecast, by Target Antigen
12.2.6.3. Market Revenue and Volume Forecast, by Radioisotope
12.2.6.4. Market Revenue and Volume Forecast, by Administration Route
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Indication
12.2.7.2. Market Revenue and Volume Forecast, by Target Antigen
12.2.7.3. Market Revenue and Volume Forecast, by Radioisotope
12.2.7.4. Market Revenue and Volume Forecast, by Administration Route
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Indication
12.2.8.2. Market Revenue and Volume Forecast, by Target Antigen
12.2.8.3. Market Revenue and Volume Forecast, by Radioisotope
12.2.8.4. Market Revenue and Volume Forecast, by Administration Route
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Indication
12.3.2. Market Revenue and Volume Forecast, by Target Antigen
12.3.3. Market Revenue and Volume Forecast, by Radioisotope
12.3.4. Market Revenue and Volume Forecast, by Administration Route
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Indication
12.3.5.2. Market Revenue and Volume Forecast, by Target Antigen
12.3.5.3. Market Revenue and Volume Forecast, by Radioisotope
12.3.5.4. Market Revenue and Volume Forecast, by Administration Route
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Indication
12.3.6.2. Market Revenue and Volume Forecast, by Target Antigen
12.3.6.3. Market Revenue and Volume Forecast, by Radioisotope
12.3.6.4. Market Revenue and Volume Forecast, by Administration Route
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Indication
12.3.7.2. Market Revenue and Volume Forecast, by Target Antigen
12.3.7.3. Market Revenue and Volume Forecast, by Radioisotope
12.3.7.4. Market Revenue and Volume Forecast, by Administration Route
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Indication
12.3.8.2. Market Revenue and Volume Forecast, by Target Antigen
12.3.8.3. Market Revenue and Volume Forecast, by Radioisotope
12.3.8.4. Market Revenue and Volume Forecast, by Administration Route
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Indication
12.4.2. Market Revenue and Volume Forecast, by Target Antigen
12.4.3. Market Revenue and Volume Forecast, by Radioisotope
12.4.4. Market Revenue and Volume Forecast, by Administration Route
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Indication
12.4.5.2. Market Revenue and Volume Forecast, by Target Antigen
12.4.5.3. Market Revenue and Volume Forecast, by Radioisotope
12.4.5.4. Market Revenue and Volume Forecast, by Administration Route
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Indication
12.4.6.2. Market Revenue and Volume Forecast, by Target Antigen
12.4.6.3. Market Revenue and Volume Forecast, by Radioisotope
12.4.6.4. Market Revenue and Volume Forecast, by Administration Route
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Indication
12.4.7.2. Market Revenue and Volume Forecast, by Target Antigen
12.4.7.3. Market Revenue and Volume Forecast, by Radioisotope
12.4.7.4. Market Revenue and Volume Forecast, by Administration Route
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Indication
12.4.8.2. Market Revenue and Volume Forecast, by Target Antigen
12.4.8.3. Market Revenue and Volume Forecast, by Radioisotope
12.4.8.4. Market Revenue and Volume Forecast, by Administration Route
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Indication
12.5.2. Market Revenue and Volume Forecast, by Target Antigen
12.5.3. Market Revenue and Volume Forecast, by Radioisotope
12.5.4. Market Revenue and Volume Forecast, by Administration Route
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Indication
12.5.5.2. Market Revenue and Volume Forecast, by Target Antigen
12.5.5.3. Market Revenue and Volume Forecast, by Radioisotope
12.5.5.4. Market Revenue and Volume Forecast, by Administration Route
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Indication
12.5.6.2. Market Revenue and Volume Forecast, by Target Antigen
12.5.6.3. Market Revenue and Volume Forecast, by Radioisotope
12.5.6.4. Market Revenue and Volume Forecast, by Administration Route
13.1. AbbVie
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Amgen
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Astra Zeneca
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Bayer
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Bristol-Myers Squibb
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Eli Lilly and Company
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Gilead Sciences
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Johnson Johnson
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Merck Co
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Novartis
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description